These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 26289996

  • 1. Resistance exercise and naproxen sodium: effects on a stable PGF2α metabolite and morphological adaptations of the upper body appendicular skeleton.
    Brewer CB, Bentley JP, Day LB, Waddell DE.
    Inflammopharmacology; 2015 Dec; 23(6):319-27. PubMed ID: 26289996
    [Abstract] [Full Text] [Related]

  • 2. Effects of selective cyclooxygenase-2 inhibition on gingival tissue levels of prostaglandin E2 and prostaglandin F2alpha and clinical parameters of chronic periodontitis.
    Vardar S, Baylas H, Huseyinov A.
    J Periodontol; 2003 Jan; 74(1):57-63. PubMed ID: 12593597
    [Abstract] [Full Text] [Related]

  • 3. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen.
    Bjarnason I, Macpherson A, Rotman H, Schupp J, Hayllar J.
    Scand J Gastroenterol; 1997 Feb; 32(2):126-30. PubMed ID: 9051872
    [Abstract] [Full Text] [Related]

  • 4. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
    Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ, Alzheimer's Disease Cooperative Study.
    JAMA; 2003 Jun 04; 289(21):2819-26. PubMed ID: 12783912
    [Abstract] [Full Text] [Related]

  • 5. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
    Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS.
    Mayo Clin Proc; 1999 Nov 04; 74(11):1095-105. PubMed ID: 10560596
    [Abstract] [Full Text] [Related]

  • 6. COX-2 selective NSAID decreases bone ingrowth in vivo.
    Goodman S, Ma T, Trindade M, Ikenoue T, Matsuura I, Wong N, Fox N, Genovese M, Regula D, Smith RL.
    J Orthop Res; 2002 Nov 04; 20(6):1164-9. PubMed ID: 12472224
    [Abstract] [Full Text] [Related]

  • 7. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
    Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS.
    J Rheumatol; 2000 Aug 04; 27(8):1876-83. PubMed ID: 10955327
    [Abstract] [Full Text] [Related]

  • 8. Effects of prostaglandins and COX-inhibiting drugs on skeletal muscle adaptations to exercise.
    Trappe TA, Liu SZ.
    J Appl Physiol (1985); 2013 Sep 04; 115(6):909-19. PubMed ID: 23539318
    [Abstract] [Full Text] [Related]

  • 9. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
    Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL, Lines CR, Gertz BJ, Curtis S, Etoricoxib Rheumatoid Arthritis Study Group.
    J Rheumatol; 2002 Aug 04; 29(8):1623-30. PubMed ID: 12180720
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen.
    Makarowski W, Zhao WW, Bevirt T, Recker DP.
    Osteoarthritis Cartilage; 2002 Apr 04; 10(4):290-6. PubMed ID: 11950252
    [Abstract] [Full Text] [Related]

  • 11. Isomer-specific effects of conjugated linoleic acid on lipid peroxidation in humans: regulation by alpha-tocopherol and cyclo-oxygenase-2 inhibitor.
    Smedman A, Vessby B, Basu S.
    Clin Sci (Lond); 2004 Jan 04; 106(1):67-73. PubMed ID: 12956622
    [Abstract] [Full Text] [Related]

  • 12. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S, Robbins J, West CR, Nemeth MA.
    Clin Ther; 2009 Jun 04; 31(6):1192-208. PubMed ID: 19695387
    [Abstract] [Full Text] [Related]

  • 13. Novel cyclooxygenase-catalyzed bioactive prostaglandin F2alpha from physiology to new principles in inflammation.
    Basu S.
    Med Res Rev; 2007 Jul 04; 27(4):435-68. PubMed ID: 17191216
    [Abstract] [Full Text] [Related]

  • 14. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population.
    Helmersson J, Vessby B, Larsson A, Basu S.
    Circulation; 2004 Apr 13; 109(14):1729-34. PubMed ID: 15037525
    [Abstract] [Full Text] [Related]

  • 15. Gastroduodenal tolerability of highly specific cyclo-oxygenase-2 inhibitor.
    Hayllar J, Bjarnason I.
    Ital J Gastroenterol; 1996 Dec 13; 28 Suppl 4():30-2. PubMed ID: 9032580
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of the specific cyclooxygenase-2 inhibitor DFP compared with naproxen sodium in patients with postoperative dental pain.
    Gottesdiener K, Mehlisch DR, Huntington M, Yuan WY, Brown P, Gertz B, Mills S.
    Clin Ther; 1999 Aug 13; 21(8):1301-12. PubMed ID: 10485502
    [Abstract] [Full Text] [Related]

  • 17. The effects of creatine monohydrate supplementation with and without D-pinitol on resistance training adaptations.
    Kerksick CM, Wilborn CD, Campbell WI, Harvey TM, Marcello BM, Roberts MD, Parker AG, Byars AG, Greenwood LD, Almada AL, Kreider RB, Greenwood M.
    J Strength Cond Res; 2009 Dec 13; 23(9):2673-82. PubMed ID: 19858753
    [Abstract] [Full Text] [Related]

  • 18. Naproxen sodium, aspirin, and placebo in primary dysmenorrhea. Reduction of pain and blood levels of prostaglandin F2-alpha metabolite.
    Rosenwaks Z, Jones GS, Henzl MR, Dubin NH, Ghodgaonkar RB, Hoffman S.
    Am J Obstet Gynecol; 1981 Jul 01; 140(5):592-8. PubMed ID: 7246695
    [Abstract] [Full Text] [Related]

  • 19. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group.
    N Engl J Med; 2000 Nov 23; 343(21):1520-8, 2 p following 1528. PubMed ID: 11087881
    [Abstract] [Full Text] [Related]

  • 20. Cyclooxygenase-mediated prostaglandin F2alpha is decreased in an elderly population treated with low-dose aspirin.
    Helmersson J, Vessby B, Larsson A, Basu S.
    Prostaglandins Leukot Essent Fatty Acids; 2005 Apr 23; 72(4):227-33. PubMed ID: 15763433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.